by aisla@raikee.fi | Oct 29, 2018 | News
Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine...
by aisla@raikee.fi | Sep 19, 2018 | News
Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä immunoterapeuttisella tuotteellaan, DM-101:llä, joka on suunnattu koivuallergian hoitoon. Tuotteella pyritään koivuallergian siedätyshoidon merkittävään...
by aisla@raikee.fi | Nov 29, 2017 | News
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company Kansalaisrahoitus. The funds...
by aisla@raikee.fi | Oct 5, 2017 | News
Desentum is approaching first-in-man clinical trials with its lead product candidate, a modified hypoallergen aimed for an immunotherapeutic treatment of birch pollen allergy. The birch pollen hypoallergen has shown promise in laboratory tests. Next, it needs to be...
by aisla@raikee.fi | Jun 14, 2017 | News
The annual congress of the European Academy of Allergy and Clinical Immunology will be in Helsinki in June 17-21. Desentum has presentations in two Oral Abstract Sessions. Espoo, Finland, 14 June 2017 – One of the world’s biggest scientific meetings in the...
by aisla@raikee.fi | Jan 23, 2017 | News
Desentum secured funding to advance their treatment targeting birch pollen allergy. ESPOO, Finland, 23 January 2017– Today, Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series...